Breast tumor cells are often resistant to tumor necrosis factor-related apoptosis-inducing ligand (tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)/APO-2 L). Here, we describe the sensitization by microtubule-interfering agents (MIAs) to TRAIL-induced apoptosis in breast tumor cells through a mitotic arrest and c-Jun N-terminal kinase (JNK)-dependent mechanism. MIA treatment resulted in BubR1-dependent mitotic arrest leading to the sustained activation of JNK and the proteasome-mediated downregulation of cellular FLICE-inhibitory protein (cFLIP) and myeloid cell leukemia-1 (Mcl-1) expression. The JNK inhibitor SP600125 abrogated MIA-induced mitotic arrest and downregulation of cFLIP and Mcl-1 and reduced the apoptosis caused by the combination of MIAs and TRAIL. Silencing of cFLIP and Mcl-1 expression by RNA interference resulted in a marked sensitization to TRAIL-induced apoptosis. Furthermore, in FLIP-overexpressing cells, MIAinduced sensitization to TRAIL-activated apoptosis was markedly reduced. In summary, our results show that mitotic arrest imposed by MIAs activates JNK and facilitates TRAIL-induced activation of an apoptotic pathway in breast tumor cells by promoting the proteasome-mediated degradation of cFLIP and Mcl-1.
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)/APO-2 L, a member of the tumor necrosis factor (TNF) gene superfamily, induces apoptosis on binding to the death domain (DD)-containing receptors TRAIL-R1/DR4 and TRAIL-R2/DR5. 1 As TRAIL induces apoptosis selectively in transformed cells of diverse origin but not in most normal cells in vitro, it is an attractive candidate for antitumor therapies. [2] [3] [4] In the western world, breast cancer is the most common neoplasia among women, emphasizing the importance of developing effective treatments. Despite the fact that many cancer cells are sensitive to TRAIL-induced apoptosis, a number of them, and in particular breast cancer cells, are resistant to TRAIL. 5 In these cases, a combination therapy using chemotherapeutic agents and TRAIL may be more suitable than using TRAIL as a single agent. Recently, we and others have reported that interferon-g, DNA-damaging drugs, ionizing radiation and cyclin-dependent kinase inhibitors can sensitize breast cancer cells to TRAIL-induced apoptosis. [6] [7] [8] [9] On binding to its proapoptotic receptors, TRAIL induces the formation of the death-inducing signaling complex (DISC), recruiting the dual adaptor Fas-associated death domain (FADD) molecule through its DD. In turn, this complex recruits the initiator caspase-8 through its death effector domain (DED), 10 which is activated at the DISC by oligomerization. The processing and activation of caspase-8 at the DISC stimulates an apoptotic cascade that provokes cell death. 11, 12 The apoptotic signal from the DISC may be inhibited by the cellular FLICE-inhibitory protein (FLIP). 13 In most cells, two alternatively spliced isoforms of cellular FLICE-inhibitory protein (cFLIP) exist: a caspase-8 homolog cFLIP L that lacks the amino acids critical for proteolytic caspase activity; and cFLIP S , which consists of only the DEDs. 13 Although the role of cFLIP in apoptotic signaling remains controversial, there is strong evidence that it displays antiapoptotic activity. [14] [15] [16] The expression of cFLIP varies in a cell type-specific manner and fluctuates in response to various stimuli. Although it can be transcriptionally controlled by the nuclear factor-kB (NF-kB) pathway, 17 altered rates of proteasomal degradation also regulate its protein activity, 18 making it a versatile inhibitor of the apoptotic responses mediated by death receptors.
Microtubules are dynamic polymers composed of a/b tubulin dimers that have important roles in various cellular functions. 19 Disruption of the spindle with microtubule-interfering agents (MIAs) such as nocodazole or taxol activates the spindle assembly checkpoint causing the arrest of cells in mitosis, 20 which may eventually lead to apoptosis. 21 Although several MIAs are successfully being used in cancer chemotherapy, 22 the development of resistance against these drugs and their inherent toxicities call for either the development of new agents with improved efficacy or the use of combination regimes with other anticancer treatments. 23 Here, we report that TRAIL-resistant human breast cancer cells can be sensitized to TRAIL-induced apoptosis by exposure to MIAs. The molecular mechanisms underlying the effects of MIAs involve the induction of a mitotic arrest and c-Jun N-terminal kinase (JNK)-dependent proteasomemediated decrease in cFLIP and Mcl-1 levels that facilitates the activation by TRAIL of the apoptotic pathway.
Results
MIAs sensitize human breast tumor cell lines to TRAILinduced apoptosis. Drugs that affect microtubules dynamics are one of the most important types of antitumor agents. To determine whether MIAs sensitize breast tumor cells to the apoptotic ligand TRAIL, several breast tumor cell lines were treated either with the microtubule-depolymerizing agent nocodazole or with the microtubule-stabilizing drug taxol before the addition of TRAIL. In MDA-MB231 and SKBr-3 cell lines, MIAs caused a significant arrest at the G2/M phase of the cell cycle ( Figure 1a) . Interestingly, in these cell lines, MIAs markedly sensitize the cells to TRAILinduced apoptosis (Figure 1b) . Similar results were obtained when apoptosis was determined by visualization of nuclear fragmentation by 4 0 6-diamidino-2-phenylindole (DAPI) staining (results not shown). In contrast, in the BT-474 cell line, MIAs only partially arrested cells at the G2/M phase and did not induce sensitization to TRAIL (Figures 1a,b) . These data were further confirmed in dose-response experiments (Figure 1c) . MDA-MB231 cells were markedly sensitized to TRAIL-induced apoptosis by MIAs and this correlated with G2/M arrest. In contrast, BT-474 cells were very resistant to G2/M arrest and apoptosis sensitization by nocodazole even at doses 100 times higher than those needed to sensitize MDA-MB231 cells to TRAIL. However, BT-474 cells can be sensitized to TRAIL by other agents such as flavopiridol and cycloheximide (Supplementary Figure S1a) , which indicates that BT-474 cells have an intact TRAIL apoptosis pathway, as previously reported by our group using FLIP siRNA. 8 Caspase activation was required for the sensitization observed as the pan-caspase inhibitor Z-VAD-fmk completely abrogated the cell death induced by the combination of MIA and TRAIL (Figure 1d) . One of the consequences of MIA-induced G2/M arrest is the detachment of cells from the extracellular matrix. Furthermore, cell detachment from the extracellular matrix may increase the susceptibility of breast tumor cells to TRAIL. 24 To further explore this issue, MDA-MB231 cells were seeded in poly-HEMA-coated tissue culture dishes to prevent cell attachment and apoptosis was assessed following incubation with TRAIL. Results shown in Figure 1e indicate that cell detachment is not sufficient to sensitize these cells to TRAIL-induced apoptosis. Taxol+TRAIL  25%   G2   G2   G2   G2   G2   G2   G2   G2  G2   G2   G2   G2   G2   G2   G2   G2   G2   G2   10 0 10 1 10 2 10 3 To get further insight into the mechanism of sensitization to TRAIL-induced apoptosis promoted by MIA in breast tumor cells, we examined different biochemical events that occur on TRAIL binding to its receptors at the cell surface. TRAIL initiates apoptosis by inducing the recruitment of the adapter molecule FADD to the apoptotic TRAIL receptors and the subsequent engagement and activation of procaspase-8.
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We determined whether caspase-8 was activated in MDA-MB231 cells by analyzing the processing of the pro-caspase to the 43/41 kDa intermediate proteolytic fragments, and through the generation of the mature p18 caspase-8 subunits on TRAIL stimulation. Accordingly, TRAIL-induced activation of caspase-8 was clearly enhanced by pretreatment with nocodazole or taxol (Figure 2a and Supplementary Figure  S1b) . Activation of caspase-8 leads to the processing of its substrate BID, generating a 15-kDa fragment that translocates to the mitochondria. 25 Data shown in Figure 2a show that only in nocodazole-pretreated cells was TRAIL capable of inducing a decrease in the level of intact Bid and the generation of truncated BID (tBID). Moreover, on death Several treatments have been shown to upregulate the expression of the TRAIL death receptors, resulting in enhanced TRAIL-induced apoptosis. 27 We therefore examined the effect of nocodazole on the surface expression of TRAIL death and decoy receptors by flow cytometry (Figure 2b ). MDA-MB231 cells only express TRAIL-R2 and -R4 on the cell surface and the expression of these TRAIL receptors at the cell membrane was not significantly altered by exposure to nocodazole (Figure 2b ). Hence, nocodazole does not appear to sensitize MDA-MB231 cells to TRAIL-induced apoptosis by modulating the surface expression of TRAIL receptors.
Treatment of breast tumor cells with MIAs alters the cellular levels of different apoptosis-related proteins. To elucidate the molecular mechanisms underlying the sensitization to TRAIL-induced apoptosis by MIAs in breast tumor cells, we determined the expression levels of different pro-and antiapoptotic proteins, which are known to be relevant to mechanisms of TRAIL signaling, in MDA-MB231 cells treated either with nocodazole or with taxol. After treatment with MIAs for times up to 24 h, no changes in the levels of Bid, Bax, procaspase-8, procaspase-9, procaspase-3, procaspase-2 and XIAP were observed (data not shown). treatment of MDA-MB231 cells with MIAs resulted in changes in expression levels and/or the electrophoretic mobility of the apoptosis-related proteins Bim, FADD and Bcl-2 (data not shown), which is indicative of alterations in their phosphorylation pattern. [28] [29] [30] Interestingly, none of these effects of MIAs were observed in the BT-474 cell line (Figure 3c ), refractory to MIA-induced sensitization to TRAIL-activated apoptosis (Figures 1b and c) .
MIA treatment causes the proteasome-mediated degradation of apoptosis-related proteins. Mcl-1 and cFLIP are short half-life proteins that are subject to constitutive polyubiquitination and subsequent degradation by the proteasome. 31, 32 To further explore the mechanism by which MIAs promoted the sensitization to TRAIL in breast tumor cells, we first examined the role of the proteasome in the loss of Mcl-1 and cFLIP proteins observed on MIAs treatment. As shown in Figure 4a , pretreatment of MDA-MB231 cells with the proteasome inhibitor MG-132 completely prevented the disappearance of both Mcl-1 and cFLIP proteins induced following 24 h exposure to either nocodazole or taxol, suggesting a role for the ubiquitinproteasome pathway in the disappearance of these antiapoptotic proteins on MIA treatment. It was recently reported that the BH3-only E3 ubiquitin ligase Mule/HectH9/ ARF-BP1/HUWE1 is responsible for the polyubiquitination of Mcl-1 in different cell types. 33 To 8, 35 To ascertain whether downregulation of these antiapoptotic proteins by nocodazole was an important event in the sensitization of breast tumor cells to TRAIL, we performed RNA interference experiments with siRNA oligonucleotides specific for cFLIP or Mcl-1. Thus, we tested whether the specific silencing of cFLIP expression by siRNA has a similar effect on TRAIL-induced apoptosis. In MDA-MB231 cells, the levels of both cFLIP L and cFLIP S were substantially reduced by a specific siRNA (Figure 5a) , whereas a similar concentration of a scrambled control siRNA did not modify cFLIP protein expression. Most importantly, silencing of cFLIP expression resulted in a clear sensitization to TRAIL-induced apoptosis (Figure 5b ) as previously reported. 8 These data correlated well with the effects of nocodazole and support the hypothesis that To further substantiate the role of cFLIP in the sensitization observed, we used MDA-MB231 cells overexpressing cFLIP L and determined the effect of nocodazole treatment on apoptosis by TRAIL. Results shown in Figure 5c show that cells overexpressing cFLIP L were clearly more resistant to nocodazole-induced sensitization to TRAIL apoptosis than cells expressing normal cFLIP levels.
Mitotic arrest imposed by MIAs activates JNK and facilitates TRAIL-induced apoptosis. Accumulated evidence indicates that altering microtubule dynamics by treatment with MIAs activates the JNK/SAPK pathway in a variety of cells. 36 On the other hand, the activity of the JNK/ SAPK pathway may regulate the sensitivity of human tumor cells to TRAIL. 37 To further investigate the mechanism of MIA-induced sensitization to TRAIL-activated apoptosis in breast tumor cells, we analyzed the activation of the JNK/ SAPK pathway in MDA-MB231 cells treated with nocodazole or taxol. We first examined the effect of MIAs on the activation of JNK/SAPK by measuring the dual phosphorylation of JNK/SAPK (Thr183/Tyr185) as a function of time. Interestingly, incubation of cells with nocodazole or taxol caused a sustained activation of (Figures 6b  and c) . Furthermore, the changes in the electrophoretic mobility of the apoptosis-related proteins FADD, Bim and Bcl-2 observed in cells treated with MIAs were markedly inhibited in the presence of the JNK/SAPK inhibitor (results not shown).
We next examined the effect of SP600125 on apoptosis induced by incubation of cells with either nocodazole or taxol and subsequently treated with TRAIL. Results in Figures 6d and e show that SP600125 drastically reduced the apoptosis elicited by the combination of MIA and TRAIL, consistent with a role of JNK/SAPK activation in the regulation of cFLIP and Mcl-1 degradation by the proteasome-and TRAIL-induced apoptosis. Interestingly, the inhibitor of JNK/SAPK specifically inhibited the apoptosis induced by MIAs and TRAIL but not by other combination treatments (flavopiridol, cycloheximide) with TRAIL, which do not cause a sustained activation of the JNK/SAPK pathway (Figure 6f and results not shown) .
To further investigate the mechanism of MIA-induced sensitization to TRAIL, we examined the importance of the mitotic checkpoint induction in the sensitization process. Mitotic checkpoint activation was assessed by monitoring the levels of BubR1 and histone H3 phosphorylation in cells treated with nocodazole. 39 As shown in Figure 7a , nocodazole treatment resulted in a shift of BubR1 to its hyperphosphorylated form and a marked phosphorylation of histone H3 in MDA-MB231 cells. Other treatments such as flavopiridol or cycloheximide, which cause SP600125-insensitive sensitization to TRAIL, did not induce mitotic arrest (Supplementary Figure S2) . Interestingly, BT-474 cells were clearly refractory to nocodazole-induced activation of these mitotic checkpointrelated events, thus confirming the cell cycle data shown in Figure 1a that indicated inefficient G2/M arrest in these cells following MIAs treatment. It has been reported that the JNK inhibitor SP600125 could abrogate spindle assembly checkpoint function in human cells by inhibiting the activity of the mitotic checkpoint kinase monopolar spindle 1 (Mps1). 40 We have investigated this issue by monitoring histone H3 phosphorylation in MDA-MB231 cells treated with nocodazole. Histone H3 phosphorylation induced by nocodazole was markedly reduced in cells treated with SP600125 (Figure 7b ), thus indicating that cells did not enter mitotic arrest under these conditions. It has been described that siRNA knockdown of BubR1 results in mitosis acceleration and spindle assembly checkpoint abrogation, 41 thus indicating that the control of BubR1 levels might be an essential regulatory step in checkpoint activity. To further study the role of the mitotic arrest imposed by MIAs in the activation of JNK and the regulation of TRAIL-induced apoptosis, we performed siRNA experiments to knock down BubR1 expression levels in MDA-MB231 cells. Silencing of BubR1 expression drastically reduced histone H3 phosphorylation (Figure 7c Figure 6a . Expression levels of the various apoptosis-related proteins were determined by western blotting with specific antibodies. GAPDH and tubulin expression were used as protein loading controls. Results are representative of at least three independent experiments. (d, e) MDA-MB231 cells were incubated for 15 h in the presence or absence of SP600125 and nocodazole (d) or taxol (e) before treatment with TRAIL for 4 h. Apoptosis was assessed as described in Materials and Methods. Error bars represent S.D. from three independent experiments. (f) MDA-MB231 cells were incubated for 15 h in the presence or absence of nocodazole (0.4 mg/ml), flavopiridol (100 nM) or cycloheximide (1 mg/ml), with or without SP600125 (25 mM). Following these incubations, cells were treated without or with TRAIL (500 ng/ml) for 6 h and apoptosis was assessed as the percentage of cells with sub-G1 DNA content. Results are the average and range of two independent experiments in duplicate altering microtubules dynamics may increase the sensitivity of breast tumor cells to the death ligand TRAIL. Although an increase in the total expression of proapoptotic TRAIL receptor proteins by taxol and other chemotherapeutic agents has been reported, 44, 45 we do not observe an upregulation of TRAIL-R1 or TRAIL-R2 at the cell surface in breast tumor cells treated with MIAs. Hence, the step(s) involved in the sensitization to TRAIL should reside downstream of ligand binding to the receptor.
We have been studying the resistance of human breast tumor cells to TRAIL and previously reported that the formation of DISC is a common target for different sensitizing regimes. 8, 46 Furthermore, resistance of tumor cells to TRAIL can be overcome by treatment with metabolic inhibitors such as cycloheximide or actinomycin D. 47 These compounds induce a strong downregulation of cFLIP expression. 48 In this regard, a potential mechanism involved in the regulation of TRAIL sensitivity is the modulation of the expression of the caspase-8 inhibitors cFLIP L and cFLIP S , 13 proteins with very short half-lives 18 that are expressed at high levels in breast tumors. 49 Although enhancement of TRAIL-induced caspase-8 activation and apoptosis does not always correlate with cFLIP levels, 46 it has been shown that different treatments can induce downregulation of cFLIP and subsequent sensitization to TRAIL-induced apoptosis. 50, 51 In our study, treatment of breast tumor cells with MIAs induced a marked downregulation of both cFLIP L and cFLIP S proteins. It is well documented that cFLIP can be transcriptionally regulated through the NF-kB pathway. 17 However, we did not observe a decrease in cFLIP mRNA in breast tumor cells treated with MIAs at concentrations that caused maximal sensitization to TRAIL (results not shown), thus excluding the transcriptional regulation of cFLIP as the major target for the inhibitory action of MIAs on cFLIP levels. cFLIP protein levels can be downregulated by proteasomal degradation 18 and this modulation may lead to TRAIL sensitization. 52 Our results show that in breast tumor cells MIA treatment leads to the proteasomemediated degradation of both cFLIP isoforms through a mitotic arrest and JNK-dependent mechanism. Inhibition of cytoskeletal dynamics results in the activation of signal transduction pathways. MIAs have been shown to induce a sustained activation of JNK in a variety of human cells through both Ras and apoptosis signal-regulating kinase (ASK1)-dependent pathways.
36 MEK1 kinase (MEKK1) is also required for the activation of JNK following exposure of cells to MIAs. 53 In this study, we have shown that inhibiting microtubule dynamics causes a sustained activation of the JNK and markedly sensitizes breast tumor cells to TRAILinduced apoptosis. We have also shown that JNK activation by MIAs requires the spindle checkpoint machinery as it is markedly abrogated in cells depleted of the mitotic checkpoint kinase BubR1. Downregulation of cFLIP and sensitization to TRAIL-induced apoptosis correlated well with the activation of JNK by MIAs in the various breast tumor cell lines examined. Regarding the mechanism of cFLIP degradation, it has been shown that JNK activation by TNF-a reduces cFLIP L stability by a mechanism involving JNK-mediated phosphorylation and activation of the E3 ubiquitin ligase Itch, which ubiquitinates cFLIP L and induces its proteasomal degradation. 34 Furthermore, in cisplatin-treated tumor cells, Itch forms a complex with cFLIP and p53 to promote cFLIP ubiquitination and degradation through the proteasome. 54 However, our siRNA data suggest that Itch is not responsible for the proteasomal degradation of cFLIP in breast tumor cells treated with MIAs, indicating that other E3 ubiquitin ligases must be involved in the degradation of cFLIP proteins following inhibition of microtubule dynamics.
The sensitizes tumor cells to TRAIL-induced apoptosis. 55 58 We show for the first time that MIAs induce the proteasomal degradation of both apoptosis inhibitors by a mechanism involving the spindle checkpoint machinery and the sustained activation of JNK. Proteasome-mediated degradation of Mcl-1 is regulated by phosphorylation. 59 In growth factor-dependent cells, Mcl-1 protein levels are regulated by growth factor signaling at the level of protein half-life through phosphorylation by GSK-3. 60 It has been suggested that JNK could be responsible for the priming phosphorylation of Mcl-1 61 necessary for the docking of GSK-3 to Mcl-1. It remains to be determined whether in breast tumor cells treated with MIAs, GSK-3 is also involved in the proteasome-mediated degradation of Mcl-1. Mcl-1 is a target for the BH3-containing E3 ubiquitin ligase Mule (also known as Huwe1, UreB1, ARF-BP1, Lasu1 and HectH9). 33 Our results indicate that Mule is required for the proteasome-mediated degradation of Mcl-1 in breast tumor cells treated with MIAs. It will be important to determine whether phosphorylation of Mcl-1 by JNK and possibly GSK-3 may regulate the direct recognition of Mcl-1 by the HECT-family member Mule.
JNK activation by MIAs also posttranslationally affects other apoptosis-related proteins such as Bim, Bcl-2 and the death receptor adaptor FADD. Although the role of these modifications on TRAIL-induced apoptosis is not clear, we cannot exclude that they may contribute to the sensitization observed. JNK-mediated phosphorylation of Bim has been proposed to mediate sensitization to TRAIL in other tumor cells. 62 Furthermore, it has been shown that under nonapoptotic conditions, Bim is sequestered by Mcl-1 and loss in Mcl-1 expression significantly enhances the mitochondrial apoptotic response to TRAIL mediated by freed Bim. 63 On the other hand, it has been reported that Bcl-2 phosphorylation by JNK is functionally linked to apoptosis induced by taxol. 64 Similarly, FADD phosphorylation through a JNK-dependent mechanism is observed in tumor cells treated with taxol and is closely associated with chemosensitivity. 65 However, the role of Bcl-2 and FADD phosphorylation by JNK in the regulation of TRAILinduced apoptosis remains to be elucidated.
In conclusion, it is likely that inhibition of microtubule function by MIAs sensitizes tumor cells to TRAIL by reducing the cellular levels of apoptosis inhibitors, which leads to the complete activation of the apoptotic machinery as we have shown in this work. The present findings provide further support for the general strategy of combining TRAIL and agents that affect the mitotic checkpoint in anticancer strategies.
Analysis of apoptosis. Cells (3 Â 10 5 per well) were treated in six-well plates as indicated in the figure legends. After treatment, hypodiploid apoptotic cells were detected by flow cytometry according to published procedures. 9 Basically, cells were washed with phosphate-buffered saline (PBS), fixed in 70% cold ethanol and then stained with propidium iodide while treating with RNAse. Quantitative analysis of the cell cycle and sub-G1 cells was carried out in a FACSCalibur cytometer using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA).
RT-PCR. RT-PCR analyses were performed according to standard protocols. Total RNA was isolated from cells with Trizol reagent (Life Technologies, Inc., Grand Island, NY, USA) as recommended by the supplier. cDNA was synthesized from 2 mg of total RNA using an RNA PCR kit (Perkin-Elmer, Indianapolis, IN, USA) with the supplied Random Hexamers under the conditions described by the manufacturer. PCR reactions were performed using specific primers for Mule (forward: 5 0 -GGGGTTATGACCCAAGAGGT-3 0 and reverse: 5 0 -CCCATCTCGAG ACTCCTCTG-3 0 ) and actin.
Immunoblot analysis of proteins. After detachment with trypsin, cells (3 Â 10 5 ) were washed with PBS, and protein content was measured following cell lysis using the Bradford reagent (Bio-Rad Laboratories, Hercules, CA, USA) before adding Laemmli sample buffer. Samples were sonicated, and proteins were resolved on SDS-polyacrylamide minigels and detected as described previously. 9 Measurements of Cyt c release. Cells (3 Â 10 5 per well) were treated in six-well plates as indicated in the figure legends. After treatment, cells were detached from the plate with RPMI/EDTA and trypsin, washed with PBS and lysed in 30 ml ice-cold lysis buffer (80 mM KCl, 250 mM sucrose, 500 mg/ml digitonin and protease inhibitors in PBS). For measurements of Cyt c release from mitochondria, cell lysates were centrifuged for 5 min at 10 000 g to separate the supernatant (cytosolic fraction) and pellet (mitochondria-containing fraction). The amount of protein in each fraction was determined by the Bradford protein assay (BIO-RAD, Hertfordshire, UK). Proteins from the supernatant and pellet were mixed with Laemmli buffer and resolved on SDS-12% PAGE minigels. Cyt c was determined by western blot analysis.
Analysis of TRAIL receptors by flow cytometry. MDA-MB231 cells were detached with RPMI 1640/EDTA, washed in ice-cold PBS and resuspended in PBS. Cells were then labeled with anti-TRAIL receptor antibodies (5 mg/ml) or no antibody (negative control), and then incubated with goat anti-mouse FITCconjugated antibody F(ab 0 ) 2 fragment. Labeled cells were analyzed by flow cytometry using the CellQuest software (Becton Dickinson, Mountain View, CA, USA).
RNA interference. siRNAs against cFLIP (5 0 -GGGACCUUCUGGAUAUUU Utt-3 0 ), Mcl-1 (5 0 -GAAACGCGGUAAUCGGACUtt-3 0 ), Mule (5 0 -GAGUUUGGAGUU UGUGAAGtt-3 0 ), BubR1 (5 0 -CUUCACUUGCGGAGAACAUtt-3 0 ), Itch (5 0 -AAGUGC UUCUCAGAAUGAUGAtt-3 0 ) and nontargeting scrambled siRNA were synthesized by Sigma Proligo (St. Louis, MO, USA). Cells were transfected with siRNAs using DharmaFECT-1 (Dharmacon, Lafayette, CO, USA) as described by the manufacturer. After 48 h, the transfection medium was replaced with regular medium before further analysis.
Statistical analysis. Data are presented as mean±S.E.M. of at least three independent experiments. Differences between treatment groups were determined by using Student's t-test. Statistical significance was evaluated by calculating P-values. P-values below 0.05 were considered significant.
